Learning about new therapies: phase 3 clinical studies--and beyond. - Wikidata - wikimedia - TriplyDB

Learning about new therapies: phase 3 clinical studies--and beyond.

Learning about new therapies: phase 3 clinical studies--and beyond.

http://www.wikidata.org/entity/Q37106427

about

Are you ready for more insulin concentrations?

P2860

Q38266858-65F8C4EF-568E-44F2-94EB-08142ADC812C

P2860

Learning about new therapies: phase 3 clinical studies--and beyond.

http://www.wikidata.org/entity/Q37106427

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Learning about new therapies: phase 3 clinical studies--and beyond.

@en

Learning about new therapies: phase 3 clinical studies--and beyond.

@nl

type

label

Learning about new therapies: phase 3 clinical studies--and beyond.

@en

Learning about new therapies: phase 3 clinical studies--and beyond.

@nl

prefLabel

Learning about new therapies: phase 3 clinical studies--and beyond.

@en

Learning about new therapies: phase 3 clinical studies--and beyond.

@nl

P1433

Q37106427-6F6476CC-6D74-4D44-BD0A-A13634D842A0

P1476

Q37106427-5AE83E9B-47D6-49B3-B984-D46B8E9B358E

P2093

Q37106427-EAD65B4C-6B3D-4056-9C78-557B5B5702CD

P2860

Q37106427-14D9FD06-F675-4BEE-9B87-5DE7564F6B30

Q37106427-15C66BF6-284B-4DE4-90EA-748E50E92603

Q37106427-1671B898-B756-432E-BEDD-875CC1B76B0E

Q37106427-2DFB6105-51D0-44AB-8487-FD614865571A

Q37106427-36664096-482E-4081-B2B3-68B089ABA698

Q37106427-4EDA02E6-4C4E-4D2A-9B71-D4BD61EA1E74

Q37106427-6AB69C95-DBE3-47CA-8D7E-BCB6E02C8994

Q37106427-71A6A50A-7845-4BE9-ACA0-3EFAC0BC297D

Q37106427-A5E0728E-9954-44B2-AFD6-0D2FCBE72160

Q37106427-B808D091-DC40-4EC6-8C0F-DFC2F5698E43

P304

Q37106427-22E118B5-F352-493A-8781-0F40857DE77B

P31

Q37106427-B5E06D77-0F18-4205-A73E-E8D8F1FCCA6B

P356

Q37106427-8261F7A8-B6ED-4CA8-9771-D12E5AEF2B2D

P407

Q37106427-E91C6973-FC1F-43FF-B943-593E2A37E742

P433

Q37106427-B71A61F5-1417-4F08-8E1F-9A874898326E

P478

Q37106427-1FDE797A-1063-4BAF-96D0-4F21E9232C52

P577

Q37106427-C6BFFF5E-9024-4994-84AA-7C88F0FC9A66

P5875

Q37106427-55B28354-D436-4B03-B343-D4DF5CEDACDF

P698

Q37106427-6589C544-E503-442C-8381-FEB1B3B5A7DC

P932

Q37106427-2A06C63D-42D7-4906-AC73-4BD994BD186B

P356

P1433

P1476

Learning about new therapies: phase 3 clinical studies--and beyond.

@en

P2093

Matthew C Riddle

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

Increased mortality of patients with diabetes reporting severe hypoglycemia.

Severe hypoglycemia predicts mortality in diabetes.

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.

Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hospitalized patients.

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

High-dose insulin therapy: is it time for U-500 insulin?

P304

2453-2455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-1019

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256086084

http://www.w3.org/2001/XMLSchema#string

P698

23970714

http://www.w3.org/2001/XMLSchema#string

P932

3747890

http://www.w3.org/2001/XMLSchema#string